Splenocytes derived from combined treatment of HCC substantially enhanced CD8+ CTL activity against 4 T1 cells as compared to splenocytes derived from control animals (Supplemental Fig. S1C). The gene discussed is CD8A; the disease is hepatocellular carcinoma.